The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A

International journal of obesity (2005)18 May 2010Cited by 37 (Europe PMC)

PMID20479765DOI10.1038/ijo.2010.87PepBankPUB-20479765

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine reduced body weight more than placebo after two weeks.
In plain wordsIn overweight or moderately obese men, tesofensine reduced body weight more than placebo.
Peptide
Tesofensine
Outcome
DecreaseBody weight
Study
n = 32
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Measurements
Additional weight loss
1.8 kg
tesofensine versus placebo
P value
< 0.0001
body weight comparison
Source sentences
Summary
Despite efforts to keep body weight and composition constant, TE induced a 1.8 kg weight loss above PL after 2 weeks' treatment (P<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976501
02HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine increased satiety ratings compared with placebo.
In plain wordsIn overweight or moderately obese men, tesofensine increased satiety ratings compared with placebo.
Peptide
Tesofensine
Outcome
IncreaseSatiety
Study
n = 32
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Source sentences
Summary
TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976502
03HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine increased fullness ratings compared with placebo.
In plain wordsIn overweight or moderately obese men, tesofensine increased fullness ratings compared with placebo.
Peptide
Tesofensine
Outcome
IncreaseFullness
Study
n = 32
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Source sentences
Summary
TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976503
04HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine lowered prospective food intake ratings compared with placebo.
In plain wordsIn overweight or moderately obese men, tesofensine lowered prospective food intake ratings compared with placebo.
Peptide
Tesofensine
Outcome
DecreaseProspective food intake
Study
n = 32
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Source sentences
Summary
TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976504
05HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine did not significantly change total daily energy expenditure compared with placebo.
In plain wordsIn overweight or moderately obese men, tesofensine did not significantly change total daily energy expenditure compared with placebo.
Peptide
Tesofensine
Outcome
No significant changeTotal 24-hour energy expenditure
Study
n = 32
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Source sentences
Summary
No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976505
06HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine increased nighttime energy expenditure versus placebo after adjustment for body composition changes.
In plain wordsIn overweight or moderately obese men, tesofensine increased nighttime energy expenditure versus placebo after adjustment for body composition changes.
Peptide
Tesofensine
Outcome
IncreaseNighttime energy expenditure
Study
n = 32
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Measurements
Nighttime energy expenditure increase
4.6%
adjusted for body composition changes
P value
< 0.05
nighttime energy expenditure
Source sentences
Summary
No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976506
07HumanRandomized controlled trialEfficacy outcome
In overweight or moderately obese men, tesofensine increased daily fat oxidation compared with placebo.
In plain wordsIn overweight or moderately obese men, tesofensine increased daily fat oxidation compared with placebo.
Peptide
Tesofensine
Outcome
Increase24-hour fat oxidation
Study
n = 32
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days · 2 weeksAs given in this study (human).
Measurements
Fat oxidation increase
18 g
24-hour tesofensine versus placebo
P value
< 0.001
fat oxidation
Source sentences
Summary
Furthermore, TE increased 24-h fat oxidation as compared with PL (18 g; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial.
Report a problemFND-2047976507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.